Core Viewpoint - The company reported a significant revenue increase and a reduction in net loss, indicating positive operational progress and potential for future growth [1] Financial Performance - Revenue for the six months ending June 30, 2025, was 294 million RMB, representing a year-on-year growth of 75.4% [1] - The net loss narrowed to 132 million RMB, a decrease of 12.6% compared to the previous year [1] - Basic loss per share was 0.17 RMB [1] Product Development and Approvals - Multiple core products showed stable growth, with successful commercialization of several products introduced from Alcon, enhancing the company's product line and market potential [1] - Research and development expenses were 39 million RMB, down 33.6% year-on-year, indicating efficient cost management [1] - The product "智维泰" (0.24% Cetirizine Eye Drops) received NMPA approval for commercialization, being the only FDA-approved anti-allergy ophthalmic drug for patients aged two and above [1] - OT-703 (ILUVIEN, Fluocinolone Acetonide Intravitreal Implant) was approved by CDE for inclusion in the Hainan Boao Lecheng International Medical Tourism Pilot Zone for real-world research applications, with patient enrollment underway [1] - The company's self-developed product OT-802 (Mydriatic Alkaloid) received CDE approval for Phase III clinical trial application, showing potential to fill the gap in the commercialization of innovative drugs for presbyopia in China [1] - Six products received production approvals during the reporting period, with commercial batch production proceeding in an orderly manner [1] - The localization production work for "优施莹" has entered the review and public announcement stage [1]
欧康维视生物-B(01477)发布中期业绩，净亏损1.32亿元，同比收窄12.6%